Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib or enasidenib plus intensive chemotherapy for newly diagnosed IDH-mutated AML or MDS-EB2
NL-OMON59739Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Mar 2019; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON59739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59739.